Jiang L, Gao J Y, Xu Z J, He S R, Hua B
Department of Radiology, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China.
Department of Pathology, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China.
Zhonghua Wai Ke Za Zhi. 2023 Feb 1;61(2):100-106. doi: 10.3760/cma.j.cn112139-20220914-00389.
To establish a newly-designed scoring system for breast imaging-reporting and data system (BI-RADS) 4 and 5 breast lesions only visible on MRI, and to examine their clinical pathway of biopsy. The BI-RADS 4 and 5 breast lesions only visible on MRI but not suspected on mammograms or ultrasound between June 2007 and December 2021 at Beijing Hospital were evaluated retrospectively. A total of 209 lesions from 184 patients were finally included. All patients were female, aged (50±11) years (range: 27 to 76 years). All lesions were confirmed by pathology and divided into malignancy and non-malignancy. The lesions were divided into mass and non-mass type using BI-RADS. The receiver operator characteristic (ROC) curve was used to evaluate the diagnostic performance of the new scoring system. Four types of pathology-obtaining pathway were used: biopsy guided by second-look ultrasound, local excision guided by lesion position information on MRI, intraductal lesion excision guided by methylene blue stain and mastectomy. The data between mass and non-mass lesions were compared by Mann-Whitney test, test or Fisher exact test,respectively. There were 124 malignant and 85 non-malignant lesions, while 100 mass and 109 non-mass lessions. The sizes between mass and non-mass lesions showed significant difference((IQR)) (7.0 (3.0) mm 25.0 (25.0) mm, =568.000, <0.01) and their BI-RADS diagnostic accuracy had no significant difference (53.0% (53/100) 65.1% (71/109), =3.184, =0.074). The areas under ROC curve of the new scoring system for evaluating mass and non-mass were 0.841 and 0.802, respectively. When taking Score 3 as threshold, it can potentially avoid 14.0% (14/100) and 4.6% (5/109) of biopsies in mass and non-mass, respectively. As to pathway of obtaining pathology, second-look ultrasound succeeded more easily in mass than non-mass (41.0% (41/100) .26.6% (29/109), =4.851, =0.028). More MRI-guided local excisions were performed in non-mass than mass (52.3% (57/109) 34.0% (34/100), =7.100, =0.008). For suspicious breast lesions detected by MRI but not suspected on X-ray or ultrasound, the new scoring system can further increase diagnostic accuracy. The second-look ultrasound plays an important role for obtaining pathology, especially for mass-type lesion.
建立一种新设计的针对仅在磁共振成像(MRI)上可见的乳腺影像报告和数据系统(BI-RADS)4类和5类乳腺病变的评分系统,并研究其活检的临床路径。回顾性评估2007年6月至2021年12月在北京医院仅在MRI上可见但在乳房X线摄影或超声检查中未被怀疑的BI-RADS 4类和5类乳腺病变。最终纳入了184例患者的209个病变。所有患者均为女性,年龄(50±11)岁(范围:27至76岁)。所有病变均经病理证实,并分为恶性和非恶性。使用BI-RADS将病变分为肿块型和非肿块型。采用受试者操作特征(ROC)曲线评估新评分系统的诊断性能。采用四种获取病理的途径:二次超声引导下活检、根据MRI上病变位置信息引导的局部切除、亚甲蓝染色引导下的导管内病变切除和乳房切除术。分别采用Mann-Whitney检验、检验或Fisher精确检验比较肿块型和非肿块型病变的数据。有124个恶性病变和85个非恶性病变,其中100个肿块型病变和109个非肿块型病变。肿块型和非肿块型病变的大小显示出显著差异(四分位距)(7.0(3.0)mm对25.0(25.0)mm,=568.000,<0.01),其BI-RADS诊断准确性无显著差异(53.0%(53/100)对65.1%(71/109),=3.184,=0.074)。新评分系统评估肿块型和非肿块型病变的ROC曲线下面积分别为0.841和0.802。以3分为阈值时,分别可避免14.0%(14/100)和4.6%(5/109)的肿块型和非肿块型病变活检。至于获取病理的途径,二次超声在肿块型病变中比在非肿块型病变中更容易成功(41.0%(41/100)对26.6%(29/109),=4.851,=0.028)。非肿块型病变比肿块型病变更多地进行了MRI引导下的局部切除(52.3%(57/109)对34.0%(34/100),=7.100,=0.008)。对于MRI检测到但X线或超声未怀疑的可疑乳腺病变,新评分系统可进一步提高诊断准确性。二次超声在获取病理方面发挥着重要作用,尤其是对于肿块型病变。